0000000000-16-091950.txt : 20161130
0000000000-16-091950.hdr.sgml : 20161130
20160908133301
ACCESSION NUMBER: 0000000000-16-091950
CONFORMED SUBMISSION TYPE: UPLOAD
PUBLIC DOCUMENT COUNT: 1
FILED AS OF DATE: 20160908
FILED FOR:
COMPANY DATA:
COMPANY CONFORMED NAME: Valeant Pharmaceuticals International, Inc.
CENTRAL INDEX KEY: 0000885590
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: A8
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: UPLOAD
BUSINESS ADDRESS:
STREET 1: 2150 ST. ELZEAR BLVD. WEST
STREET 2: LAVAL
CITY: QUEBEC
STATE: A8
ZIP: H7L 4A8
BUSINESS PHONE: 514-744-6792
MAIL ADDRESS:
STREET 1: 2150 ST. ELZEAR BLVD. WEST
STREET 2: LAVAL
CITY: QUEBEC
STATE: A8
ZIP: H7L 4A8
FORMER COMPANY:
FORMER CONFORMED NAME: BIOVAIL Corp
DATE OF NAME CHANGE: 20100416
FORMER COMPANY:
FORMER CONFORMED NAME: BIOVAIL CORP INTERNATIONAL
DATE OF NAME CHANGE: 19960522
PUBLIC REFERENCE ACCESSION NUMBER: 0000885590-16-000101
LETTER
1
filename1.pdf
begin 644 filename1.pdf
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M,S,@,"!2+U-I>F4@,38T+U1Y<&4O6%)E9B]76S$@,R Q73X^#8P+"EK<&M@8'!B('QW\5_%Q@$&Q@:H$) P,K ."L<2/,"L0!(@%$-J%>K
M8=X!E02A -8,Y@5,2Q@S&6XQ)"EK'V![).JP>PU0T6RP7@X&QK/^#& WL$V&
MV\S#P/A0#600$)\ "# LQ<;O0T*96YD7!E+T]B:E-T;3X^],N#$!V_*)\(3J *WG@=^-2-"HJ'F1&@8YEJ H"4Y/:7]XM:F)?$#3OM?
M%[-D7MX1R3@]B]?G-EG4@5SM.V&"&(UL95)W-.%.PWREC=FG[0ZOQ:
MQMK8X5R44=_H BEK[VRG2!C'.+HMKM&-K_D?;,T3_];$U/UO%T\M2[?V_UO@
M_R) _R N+.+H29"^2V\S!"*=)6D_+9*V/TKRHCR[B_.&!%L8 E$1'!-Z$=##B]/K^ID3H3O-[ZS#< IDZF!8":S"/B*>U9F@L:IT6Y9U
MY^Y&YE8#CCK>U6W+.^@W>0%;S#@XUNAJEL+Z7J79A[[J'%X'0<5W(:;H_X\N[''X'"]7MH50I ]#]O?
M=:.,DJ6%:]%EI\D_OF-8"$B*/,1R9,+./1-Q'M873<15^ OW3.3I\ ]>+Y%F
MZ#[2?OB7+A78&A&ZUA>X1]'>+'PV'EYO"CB5$T;
M;-+AC'! RX]\4&Y. WV8BQ9XP*(+?_>:3?SY-X>1A+X K;L@1\-BR1AV1Z0'%W&ZME7Y?8--M-;&!2Y35Y2%[3
MO#K=[P(, -U>^$ -"F5N9'-T!0D3Z8/*BV[ HJR56OI?WWO9/=QG)R(C(8
M^9B=F9W;=7+7F6I7; S'IZ2_,^A3%;%OFH*4[7-[2U,
MYS.8YF&0O*- &>2[,*! [(>"(AJU J4RU!GD=1@0V+NO]V&PCB!^@OQC&"QL
M,2R6,T@\PM/6F+8>T_XGF#(D3 "W>D3T@D.9[U8#A9AF3ES"YG]W,@?D-*9JC4R="R
MJ+[!IW@B(M,>SMV=%U+&,,V&A4(*Y8,+Y7 #^(M\S\W2$;-"HLS>0L)>(>'*
M)FRCY0SEB#ZLP'9>02>@V,4!]/[GL,OC<9?9
M=2&#@G74H6_,-+-KN2EUX?[LMU-&"!_*6$5=&:=1LRW=D9O=QI=/1C$=
M4H[>N!II.R,NZB/)XG<\R7KEC3-G*N?SE_L-CY4[ZE][][W5']6V;$P\H22Z
M/NK#7P$& (EW-F$-"F5N9'-T_ 2AQ@<%]RT#_O'^Q>[5TU9C+$)
MQD+(]QZ=0G _X+UI^FDWYM[-7>
M:[:MRQQWV9?%M?YX%AAPL
MJXIZ ,X8*V*\;&MC0J_V"^VYJU"H34+;H=Z@A1^1",N[!<#L'JZN9G>+U0V$
MZVN8WRS@' 0QI+;@O!?Z#>2A0*UU26-SA'N>.;8GL]M#09Q(/?%Z/E9T%AOZ
M3I_K)UAQ);&G))=:-"NPUYK')A6\0R>58EAE6$.F$I08.I40A7==9J/R\A%Y
M3@EWPM#*2?A.K(YB\ (J)U2G:UG_X9EG?Y%PL@+F)+5^V0KX06K)D*?CD!2I
M13 =O%$E<42)\2*H$\AGCFX2G1@SE-FMQ@58
M[\YHR1P1P<:4MU? ;R6FX_V0#NU[#8-7S=I>[4-1T]$53;JEF$!EV9[F14MA
M.W"%_H>[3,"DN7E- J70)V@IN.A&Q$6M50NM2A__W\Q,I9..&8O,9D*^
MD[GWY-QI/1*@3S"_:[?&\W8+QK,A0.<>NMW.;'@[ E2]'@Q&0QB$7001'@04
MC@L).O-<9S#?MEOQ*1&K=8V=4$3RN:/,D"U5:6EFN'&Q%$4*=ED-9BG6([@/2I>T7#E8HEA</3[X9R9U*C(Y+C@,6XU#5)L?!F6(%'4_*@
M('\\H*9]:FQ6I?$_L/J?V-%4]>QHVZ=U#T\\K6*[626DC^_6KXT[J,V)6%H]
MI4&C$LZ>)>A/]'"GDGHOTKVM2<$S]D"MJF/#4$G0';%FL4:U)^]";!TO*Q+Z
M2/FV]5/S).NJ7LX+GICM,B9BI?"AQI